22-GI-127-RP: Phase 2 Single-Arm Study of Nanoliposomal Irinotecan with Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of GI, Unknown, or Pancreatic Origi

Grants and Contracts Details

Description

22-GI-127-RP: Phase 2 Single-Arm Study of Nanoliposomal Irinotecan with Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of GI, Unknown, or Pancreatic Origin Primary Objective 1.To determine the objective response rate of nanoliposomal irinotecan (Nal-IRI) + fluorouracil (5-FU) and leucovorin in patients with refractory advanced high-grade neuroendocrine cancer of GI, unknown, or pancreatic origin. Secondary Objective 1.To determine overall survival, progression-free survival, time to treatment failure, safety, clinical response and, quality of life (QOL) changes resulting from the combination treatment of nanoliposomal irinotecan (Nal-IRI) + fluorouracil (5-FU) and leucovorin.
StatusFinished
Effective start/end date9/7/229/7/22

Funding

  • Roswell Park Cancer Institute Corporation: $2.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.